109162 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone Phosphorothioates
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#2102Antisense nucleic acids
#2103TMPRSS6 iRNA compositions and methods of use thereof
#2104Anti-TNF compounds
#2105Neutral nanotransporters
#2106Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#2107COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#2108Antisense nucleic acids
#2109Antisense nucleic acids
#2110Oligonucleotides, compositions and methods thereof
#2111Modulation of GYS1 expression
#2112MIR-92 INHIBITORS AND USES THEREOF
#2113Natural cryptic exon removal by pairs of antisense oligonucleotides
#2114RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#2115Anti-connexin compounds targeted to connexins and methods of use thereof
#2116RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
#2117POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE
#2118Nucleic acid-polypeptide compositions and uses thereof
#2119Conjugated oligonucleotides
#2120Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions
#2121Peptide nucleic acid complex having improved cell permeability and pharmaceutical composition comprising same
#2122Nucleic acids and methods for the treatment of Pompe disease
#2123MODULATION OF TRANSTHYRETIN EXPRESSION
#2124OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOTIDES AND USES THEREOF
#2125Modified RNAi polynucleotides and uses thereof
#2126Reduced size self-delivering RNAI compounds
#2127Targeted nucleic acid conjugate compositions
#2128Composition for delivery of genetic material
#2129Targeting MicroRNAs for Metabolic Disorders
#2130Methods for treatment of polycystic kidney disease
#2131Compositions and methods for inhibiting expression of the ALAS1 gene
#2132Allele-specific gene suppression
#2133MicroRNA Compounds and Methods for Modulating MIR-122
#2134Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2135Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
#2136Compositions and methods for modulating neuronal excitability and motor behavior
#2137STANDARDIZED NEURONAL CELL ASSAYS FROM PRIMATE SPECIES
#2138TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS AND OLIGONUCLEOTIDE FORMULATIONS
#2139Pan-genotypic agents against influenza virus and methods of using the same
#2140LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling
#2141Oligomer-conjugate complexes and their use
#2142Modulating apolipoprotein (a) expression
#2143GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
#2144COMBINATION THERAPY WITH CPG TLR9 LIGAND
#2145SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III
#2146MIR-29 MIMICS AND USES THEREOF
#2147Compositions and methods for inhibiting expression of TMPRSS6 gene
#2148Single-stranded oligonucleotide
#2149METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#2150COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
#2151Targeting AMP deaminase 2 for ameliorating craving for sugar and other substances
#2152Complex containing oligonucleotide having immunopotentiating activity and use thereof
#2153METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#2154Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#2155Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#2156siRNA And Their Use In Methods And Compositions For Inhibiting The Expression Of The ORAI1 Gene
#2157Chiral design
#2158Oligonucleotide compositions and uses thereof
#2159GNAQ targeted dsRNA compositions and methods for inhibiting expression
#2160Methods of Treating Colorectal Cancer
#2161Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53
#2162Compositions and methods for treating diabetic retinopathy
#2163Treatment of cancer by systemic administration of Dbait molecules
#2164Defined multi-conjugate oligonucleotides
#2165In vivo gene silencing by chemically modified and stable siRNA
#2166DOWNREGULATING MIR-132 FOR THE TREATMENT OF LIPID RELATED DISORDERS
#2167RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
#2168RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
#2169Methods of modulating KEAP1
#2170Enhancing plasmin activity to prevent soft tissue calcification
#2171Modulation of DYRK1B expression
#2172Methods Of Treatment For Alpha-1 Antitrypsin Deficiency
#2173Antisense oligomers and uses thereof
#2174Modulation of angiopoietin-like 3 expression
#2175SIRNA, PHARMACEUTICAL COMPOSITION AND CONJUGATE WHICH CONTAIN SIRNA, AND USES THEREOF
#2176RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2177Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2178Multimeric oligonucleotide compounds
#2179Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2180Methods and compositions for inhibiting PMP22 expression
#2181Cancer treatment through RLIP76 partial depletion
#2182Nucleic acid-polypeptide compositions and uses thereof
#2183Nucleic acid-polypeptide compositions and uses thereof
#2184Approach for treating inflammatory disorders
#2185ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#2186Methods of treating intestinal fibrosis using SMAD7 inhibition
#2187COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#2188Compositions and methods for inhibiting expression of CD274/PD-L1 gene
#2189MODULATORS OF COMPLEMENT FACTOR B
#2190APTAMERS FOR ORAL CARE APPLICATIONS
#2191Aptamers for consumer product compositions
#2192Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
#2193Structure-guided chemical modification of guide RNA and its applications
#2194PLANT GENOME MODIFICATION USING GUIDE RNA/CAS ENDONUCLEASE SYSTEMS AND METHODS OF USE
#2195MODULATORS OF KLK3 ERNA
#2196TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#2197COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT
#2198Targeted RNA editing
#2199Modified RNAi agents
#2200High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof
#2201RNA complexes that inhibit melanin production
#2202Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof
#2203SYNTHETIC GUIDE RNA FOR CRISPR/CAS ACTIVATOR SYSTEMS
#2204Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
#2205Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity
#2206Two-tailed self-delivering siRNA
#2207Oligonucleotides
#2208Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#2209Oligonucleotide compositions with enhanced efficiency
#2210Antisense oligonucleotides for the treatment of Usher syndrome type 2
#2211Methods for modulating Ataxin 2 expression
#2212Compositions and methods for modulating angiopoietin-like 3 expression
#2213COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE
#2214PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS
#2215RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#2216COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
#2217RNAi agents for inhibiting expression of alpha-ENaC and methods of use
#2218TLR inhibitory oligonucleotides and their use
#2219METHODS FOR REDUCING ATAXIN-2 EXPRESSION
#2220Anti-ADAM33 oligonucleotides and related methods
#2221Methods of treating cancer by inhibition of DNA repair proteins using antisense based therapies
#2222RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
#2223DOUBLE-STRANDED OLIGONUCLEOTIDES
#2224SELECTIVE REDUCTION OF ALLELIC VARIANTS
#2225COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
#2226Nucleic acid-polypeptide compositions and uses thereof
#2227Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#2228Compositions and methods for inhibiting HMGB1 expression
#2229PLANT GENOME MODIFICATION USING GUIDE RNA/CAS ENDONUCLEASE SYSTEMS AND METHODS OF USE
#2230Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
#2231RNA interference in dermal and fibrotic indications
#2232Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2233Compositions and methods for modulation of IKBKAP splicing
#2234Nucleic acid-polypeptide compositions and uses thereof
#2235Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
#2236Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#2237Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
#2238Methods for reducing LRRK2 expression
#2239Targeted augmentation of nuclear gene output
#2240Methods and compositions for managing vascular conditions
#2241Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes
#2242RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#2243Compositions and methods for immunooncology
#2244RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
#2245MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#2246Organic compositions to treat beta-ENaC-related diseases
#2247MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#2248Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
#2249Serpina1 iRNA compositions and methods of use thereof
#2250Cancer treatment
#2251Methods of reducing expression of X-inactivation escapee genes and autosomal genes
#2252Compositions and their uses directed to huntingtin
#2253siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene
#2254IL-34 ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USING SAME
#2255Splice-switching oligonucleotides and methods of use
#2256Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3
#2257RNA interference in skin indications
#2258Nucleic acid nanostructures with core motifs
#2259COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#2260MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2)
#2261STAT3 inhibitors and uses thereof
#2262RIG-I ligands and methods for producing them
#2263COMPOUNDS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION FOR IMPROVING A DIABETIC PROFILE
#2264Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
#2265Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
#2266Nanoparticle formulations for delivery of nucleic acid complexes
#2267MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#2268Targeting MicroRNAs for the Treatment of Fibrosis
#2269Linkage modified oligomeric compounds
#2270Methods for Treatment of Alport Syndrome
#2271COMPOSITIONS AND METHODS FOR MODULATING SMN GENE FAMILY EXPRESSION
#2272TLR MODULATORS AND METHODS OF USE
#2273Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion
#2274Adjuvant composition
#2275Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
#2276Compositions and methods for modulating apolipoprotein (a) expression
#2277Compositions and methods for modulating apolipoprotein C-III expression
#2278MODULATION OF TRANSTHYRETIN EXPRESSION
#2279Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
#2280MODULATION OF TRANSTHYRETIN EXPRESSION
#2281Compositions and their uses directed to huntingtin
#2282Oligonucleotide-based inhibitors comprising locked nucleic acid motif
#2283Modulation of SMN expression
#2284Compounds and methods for modulation of DUX4
#2285MODULATORS OF KRAS EXPRESSION
#2286Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#2287AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#2288METHODS FOR THE TREATMENT OF ALOPECIA AREATA UTILIZING GENE MODULATION APPROACHES
#2289PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
#2290Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin
#2291Modified iRNA agents
#2292Conjugated antisense compounds and their use
#2293Methods and compositions for modulating apolipoprotein (a) expression
#2294Targeting microRNAs for metabolic disorders
#2295Oligonucleotide conjugates
#2296Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17
#2297COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#2298RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#2299MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS
#2300Notch 1 specific siRNA molecule
#2301MiR-92 inhibitors and uses thereof
#2302ANTISENSE DESIGN
#2303ANTISENSE DESIGN
#2304Methods and compositions for modlating apolipoprotein (A) expression
#2305ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
#2306Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#2307Compositions and methods for inhibiting gene expression of Hif2alpha
#2308Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#2309METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#2310Compounds and Methods for the Treatment of Inflammatory Diseases of the CNS
#2311Cell penetrating protein-antibody conjugates and methods of use
#2312Modulation of TMPRSS6 expression
#2313Multimeric oligonucleotides having decreased kidney clearance
#2314Compositions and methods for modulating MECP2 expression
#2315NUCLEIC ACID COMPLEX
#2316THERAPEUTIC OLIGONUCLEOTIDES
#2317SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS
#2318Sterile formulation comprising a stable phosphorothioate oligonucleotide
#2319Compositions and methods for inhibiting expression of the PCSK9 gene
#2320XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2321MicroRNA-328 anti-sense composition and therapeutic use
#2322Oligonucleotide compositions and methods thereof
#2323Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy
#2324TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE
#2325Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#2326Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ)
#2327COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS
#2328Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
#2329Micromirs
#2330Compositions and methods for inhibiting expression of RRM2 genes
#2331Glucokinase (GCK) iRNA compositions and methods of use thereof
#2332RNA interference mediated inhibition of hepatitis B Virus (HBV) gene expression using short interfering nucleic acid (siNA)
#2333Compositions and methods for inhibiting gene expression of LPA
#2334Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#2335Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
#2336Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
#2337SEPTIN PROTEINS AS NOVEL BIOMARKERS FOR DETECTION AND TREATMENT OF MÜLLERIAN CANCERS
#2338METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
#2339Nucleic acid functionalized nanoparticles for therapeutic applications
#2340Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
#2341Methods for treating inflammatory bowel disease
#2342Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#2343OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA
#2344MODULATION OF TRANSTHYRETIN EXPRESSION
#2345MODULATION OF TRANSTHYRETIN EXPRESSION
#2346MODULATION OF TRANSTHYRETIN EXPRESSION
#2347MODULATION OF TRANSTHYRETIN EXPRESSION
#2348MODULATION OF TRANSTHYRETIN EXPRESSION
#2349MODULATION OF TRANSTHYRETIN EXPRESSION
#2350MODULATION OF TRANSTHYRETIN EXPRESSION
#2351MODULATION OF TRANSTHYRETIN EXPRESSION
#2352MODULATION OF TRANSTHYRETIN EXPRESSION
#2353MODULATION OF TRANSTHYRETIN EXPRESSION
#2354CRISPR-BASED COMPOSITIONS AND METHODS OF USE
#2355Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
#2356Targeting microRNAs for metabolic disorders
#2357Antisense molecules and methods for treating pathologies
#2358Allele specific modulators of P23H rhodopsin
#2359Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof
#2360MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
#2361Micro-RNA family that modulates extracellular matrix genes and uses thereof
#2362Tau antisense oligomers and uses thereof
#2363Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells
#2364Method for generating aptamers with improved off-rates
#2365Restoration of the CFTR function by splicing modulation
#2366RNAi inhibition of alpha-ENaC expression
#2367UNA oligomers and compositions for treating amyloidosis
#2368Chemical modification of short small hairpin RNAs for inhibition of gene expression
#2369Compounds and methods for increasing antisense activity
#2370Single-stranded oligonucleotides for use in the medical treatment of skin disorders
#2371Antisense nucleic acids
#2372MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#2373Methods for modulating expression of C9ORF72 antisense transcript
#2374Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof
#2375Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof
#2376Compositions and methods for inhibiting expression of the LECT2 gene
#2377Modified oligonucleotides and methods of use
#2378Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
#2379Oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and application thereof
#2380Stabilized STAT3 decoy oligonucleotides and uses therefor
#2381Modulation of nuclear-retained RNA
#2382Targeting microRNAs for the treatment of liver cancer
#2383MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
#2384Antisense compounds targeting genes associated with cystic fibrosis
#2385Compounds and methods for reducing Tau expression
#2386Compositions for modulating expression of C9ORF72 antisense transcript
#2387Chemically modified guide RNAs for CRISPR/CAS-mediated gene regulation
#2388Targeting hepatitis B virus (HBV) host factors
#2389Stereospecific Phosphorothioate LNA
#2390Treatment of genetic disorders associated with DNA repeat instability
#2391CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS
#2392Compounds and methods for modulating TMPRSS6 expression
#2393Therapeutic UNA oligomers and uses thereof
#2394Short interfering nucleic acid (siNA) compositions
#2395RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#2396Organic compositions to treat EPAS1-related diseases
#2397Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
#2398Oligonucleotide compounds for targeting huntingtin mRNA
#2399Inhibitors of MYH7B and uses thereof
#2400Compositions for modulating Tau expression